Diaxonhit S.A. (ALEHT) - Product Pipeline Analysis, 2015 Update

Date: July 22, 2015
Pages: 39
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D58A0A151ADEN
Leaflet:

Download PDF Leaflet

Diaxonhit S.A. (ALEHT) - Product Pipeline Analysis, 2015 Update
Summary

Diaxonhit S.A. (Diaxonhit) is a biotechnology company that offers diagnostic products. The company’s activities include discovery to the marketing of specialty diagnostic products. Its products include TQS used in treatment of teanusBJI InoPlex used to treatment of prosthetic infection and EHT Dx15 used for the treatment of thyroid cancer. Diaxonhit serves wide range of therapeutic areas such as infectious diseases Alzheimer's disease, and cancer. The company commercializes in vitro diagnostic kits, instruments and in vitro diagnostic kits and instruments through its affiliate Ingen. It operates in the US, Canada. The company was formerly known as ExonHit S.A. Diaxonhit is headquartered in Paris, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Diaxonhit S.A.
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Diaxonhit S.A. Company Snapshot
Diaxonhit S.A. Company Overview
Key Information
Diaxonhit S.A. Pipeline Products and Clinical Trials Overview
Diaxonhit S.A. – Pipeline Analysis Overview
Key Facts
Diaxonhit S.A. - Major Products and Services
Diaxonhit S.A. Pipeline Products by Development Stage
Diaxonhit S.A. Clinical Trials by Trial Status
Diaxonhit S.A. Pipeline Products Overview
BJI InoPlex 2nd Generation Assay
BJI InoPlex 2nd Generation Assay Product Overview
CO-3S Companion Diagnostic Assay
CO-3S Companion Diagnostic Assay Product Overview
Companion Diagnostic Test - Breast Cancer
Companion Diagnostic Test - Breast Cancer Product Overview
DIAG-3S Diagnostic Assay
DIAG-3S Diagnostic Assay Product Overview
EHT Dx 11
EHT Dx 11 Product Overview
EHT Dx 12
EHT Dx 12 Product Overview
EHT Dx13
EHT Dx13 Product Overview
EHT Dx14
EHT Dx14 Product Overview
EHT Dx15
EHT Dx15 Product Overview
EHT Dx15 Clinical Trial
EHT Dx23
EHT Dx23 Product Overview
Therapeutic Drug Monitoring Test - Resistant Cancer
Therapeutic Drug Monitoring Test - Resistant Cancer Product Overview
Diaxonhit S.A. - Key Competitors
Diaxonhit S.A. - Key Employees
Diaxonhit S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Diaxonhit S.A., Recent Developments
Mar 26, 2015: Diaxonhit Announces 2014 Annual Results
Jan 26, 2015: DIAXONHIT – 2014 Consolidated Income
Jan 14, 2015: DIAXONHIT announces the CE marking of the BJI InoPlex test and its commercial launch
Nov 18, 2014: Diaxonhit: CITHY clinical study starts for Dx15 molecular test validation
Mar 26, 2014: Diaxonhit reports 2013 results
Jan 28, 2014: 2013 consolidated income increases to €30.5 million 11% growth of in vitro diagnostic product sales
Jan 13, 2014: Diaxonhit enters into a distribution agreement with SAMSUNG ' Health Medical Equipment ' division for commercialization of point of care diagnostic tests
Oct 16, 2013: Diaxonhit enters into exclusive partnership agreement with Japanese Tosoh Group for marketing immunoassay instruments
Sep 17, 2013: Diaxonhit Announces Half-year 2013 results
Apr 23, 2013: Diaxonhit Wins Contract From AGEPS
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Diaxonhit S.A., Key Facts
Diaxonhit S.A. Pipeline Products and Clinical Trials Overview
Diaxonhit S.A. Pipeline Products by Equipment Type
Diaxonhit S.A. Pipeline Products by Indication
Diaxonhit S.A. Clinical Trials by Trial Status
Diaxonhit S.A., Key Facts
Diaxonhit S.A., Major Products and Services
Diaxonhit S.A. Number of Pipeline Products by Development Stage
Diaxonhit S.A. Pipeline Products Summary by Development Stage
Diaxonhit S.A. Clinical Trials by Trial Status
Diaxonhit S.A. Clinical Trials Summary
BJI InoPlex 2nd Generation Assay - Product Status
BJI InoPlex 2nd Generation Assay - Product Description
CO-3S Companion Diagnostic Assay - Product Status
CO-3S Companion Diagnostic Assay - Product Description
Companion Diagnostic Test - Breast Cancer - Product Status
Companion Diagnostic Test - Breast Cancer - Product Description
DIAG-3S Diagnostic Assay - Product Status
DIAG-3S Diagnostic Assay - Product Description
EHT Dx 11 - Product Status
EHT Dx 11 - Product Description
EHT Dx 12 - Product Status
EHT Dx 12 - Product Description
EHT Dx13 - Product Status
EHT Dx13 - Product Description
EHT Dx14 - Product Status
EHT Dx14 - Product Description
EHT Dx15 - Product Status
EHT Dx15 - Product Description
EHT Dx15 - Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule with Indeterminate Cytological Analysis
EHT Dx23 - Product Status
EHT Dx23 - Product Description
Therapeutic Drug Monitoring Test - Resistant Cancer - Product Status
Therapeutic Drug Monitoring Test - Resistant Cancer - Product Description
Diaxonhit S.A., Key Employees
Diaxonhit S.A., Subsidiaries

LIST OF FIGURES

Diaxonhit S.A. Pipeline Products by Equipment Type
Diaxonhit S.A. Pipeline Products by Development Stage
Diaxonhit S.A. Clinical Trials by Trial Status
Skip to top


Ask Your Question

Diaxonhit S.A. (ALEHT) - Product Pipeline Analysis, 2015 Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: